Open Orphan (LON:ORPH) has hailed a new three-year contract with a ‘tier-one’ German pharmaceuticals company. Stepping up to Executive Chairman from CEO, Cathal Friel tells Proactive London his new role will be focussing on investor relations and 'telling the story'. He's excited about the story too, talking enthusiastically about where Open Orphan is heading now and re-capping what's happened over the last few weeks. Friel touches on the new deal saying it guarantees “significant annual revenues” with work expected to get underway this month.
Open Orphan unit Venn Life Sciences will provide the new customer pharmacokinetic services which will allow researchers to decide on dosing and assess drug side-effects.
10 Jan 20